Sanifit to Participate in the 2021 ICR Conference


Palma, Spain and San Diego, USA, January 7, 2021 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced its participation in the 2021 ICR Conference. Joan Perelló, Ph.D., Chief Executive Officer, will participate in a virtual fireside chat led by Christopher Raymond, Managing Director and Senior Research Analyst at Piper Sandler on Thursday, January 14, 2021 at 10:00 a.m. EST. Management will be available for one-on-one meetings with investors throughout the day.


About Sanifit

Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders. The Company is a spin-off from the University of the Balearic Islands and has offices in Spain and the U.S. Sanifit’s lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, and showed a significant reduction in progression of coronary calcification in a Phase 2b study among hemodialysis patients. A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease in end-stage kidney disease patients as a second indication for SNF472. For more information, please visit



Joan Perelló, Ph.D., CEO
Adam Levy, CFO


Consilium Strategic Communications
Amber Fennell, Chris Welsh, Sarah Wilson
Tel: +44 (0) 20 3709 5700